Loading stock data...
AbCellera Biologics Inc. (ABCL) Company Information
Complete company information for ABCL including business overview, key executives, headquarters location, corporate structure, and company details. Learn about ABCLleadership team and business operations.
Company Profile
AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Sector: Healthcare
Industry: Biotechnology
Website: https://www.abcellera.com
Headquarters: 150 West 4th Ave, Vancouver, BC V5Y 1G6, Canada
Phone: 604 559 9005
Full Time Employees: 596
Key Executives:
CEO, President & Chairperson: Dr. Carl L.G. Hansen Ph.D.Total Pay: $746,836
Chief Financial Officer: Mr. Andrew Booth M.B.A.Total Pay: $671,720
CTO & Director: Dr. Veronique Lecault Ph.D.Total Pay: $667,706
Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer: Mr. Tryn T. Stimart Esq., J.D., M.Sc.Total Pay: $685,080
Vice President of Communications: Ms. Tiffany Chiu B.Sc., Ph.D.
Director of Corporate Development: Graham Craig M.Sc.
Governance Risk Metrics:
Overall Risk: 7/10
Audit Risk: 7/10
Board Risk: 9/10
Compensation Risk: 8/10
Additional Information:
Market Cap: $1.25B
Enterprise Value: $871.00M
Shares Outstanding: 298.83M
Float Shares: 202.75M
Last Fiscal Year End: 12/31/2024
Next Fiscal Year End: 12/31/2025
Most Recent Quarter: 6/30/2025